Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

All Issues

Cytopathology in focus—Predictive markers in cytopathology: programmed death ligand-1

August 2026—Although cytologists and cytopathologists expend considerable effort in screening, risk stratification, diagnosis, staging, and prognostication, clinicians are increasingly demanding ancillary testing that predicts response or resistance to the broad range of therapeutic agents available to them. In advanced-stage non-small cell lung carcinoma, these therapies include tyrosine kinase and other small-molecule inhibitors, bispecific antibodies, and antibody-drug conjugates.

Cytopathology in focus—What sets pediatric cytology apart?

August 2026—Pediatric pathology remains a relatively small subspecialty within anatomic pathology. The American Board of Pathology since 1990 has issued only 648 subspecialty certificates in pediatric pathology, and between 2020 and 2024, only 14 to 21 candidates sat for the pediatric pathology certifying examination each year.

From the President’s Desk

August 2026—At the upcoming CAP26 annual meeting in Las Vegas, you might notice key differences compared with our past meetings. We know some elements that were once compelling reasons to attend conferences, such as CME credits, are no longer the draw they used to be.

Clinical pathology selected abstracts

August 2026—Patients undergoing cardiac surgery have a higher risk of excessive bleeding and complications due to dilutional effects during surgery and activation and consumption of platelets and coagulation factors. Increasing recognition of the related morbidity and mortality has heightened interest in patient blood management, including autologous blood salvage (ABS) using an automated cell-salvage system for safe and effective blood conservation in cardiac surgery with cardiopulmonary bypass. Of importance in adult and pediatric populations is that reinfused washed red blood cells be of high quality to prevent adverse events from cytolysis and activation processes and severe and fatal complications.

Anatomic pathology selected abstracts

August 2026—Primary perianal adenocarcinoma of intestinal type has been described in recent literature and proposed as a subtype of extramucosal anal adenocarcinoma. Whether this represents a unique entity remains to be elucidated. The authors conducted a study in which they analyzed the clinicopathologic and genomic features of 14 cases of primary perianal adenocarcinoma of intestinal type (PPAI).

Molecular pathology selected abstracts

August 2026—Kawasaki disease is an acute vasculitis of childhood and the most common cause of acquired heart disease in children worldwide. Up to 25 percent of untreated patients develop coronary artery aneurysms. The variable clinical presentation of Kawasaki disease (KD) complicates diagnosis, treatment, and understanding of the disease and highlights the need for molecular tools to stratify patients into biologically meaningful subgroups.

Q&A column

August 2026
Q. Are laboratories sticking to the established standard of spinning whole blood coagulation test tubes within four hours of specimen collection or are most changing to a 24-hour window (with some exceptions) per Clinical and Laboratory Standards Institute guidelines? Read answer.
Q. I am evaluating a large, well-circumscribed necrotic pelvic peritoneal implant in a case of serous borderline tumor (SBT) of the ovary. The implant shows nonviable necrotic tissue displaying only residual ghost papillary outlines with calcification. My initial interpretation is the peritoneal nodule is an invasive implant because it is large. I am assuming the necrosis represents infiltrative, destructive, and expansile neoplastic cells that form the large nodule (17 mm). I considered upgrading the SBT to low-grade serous carcinoma (LGSC) because of the presence of this implant. However, since the implant is necrotic, I cannot reliably evaluate for tumor cells. In addition, it is rare to have an invasive implant without an invasive component at the primary site. What is your opinion regarding this implant? Read answer.

Newsbytes

August 2026—Pathologists and other cross-departmental staff at Beth Israel Lahey Health, in Boston, recently used an “all for one and one for all” approach to decision-making in evaluating image-management systems for purchase.

Put It on the Board

August 2026—Roche in June launched its Axelios 1, a next-generation single-molecule sequencing platform that it says will address bottlenecks in genomics and potentially in clinical research.

MARKETPLACE

TRENDING